Adlai NortyeANL -1.57% ROE % is 0.00% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 1,255 Biotechnology companies, Adlai Nortye ranks worse than 94.82% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Adlai Nortye's annualized net income for the quarter that ended in Dec. 2025 was $-34.39 Mil. Adlai Nortye's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was $-0.20 Mil. Therefore, Adlai Nortye's annualized ROE % for the quarter that ended in Dec. 2025 was N/A%.
The historical rank and industry rank for Adlai Nortye's ROE % or its related term are showing as below:
ANL'
s ROE % Range Over the Past 10 Years
Min: -424.91 Med: -258.6 Max: -103.19
Current: -424.91
During the past 5 years, Adlai Nortye's highest ROE % was -103.19%. The lowest was -424.91%. And the median was -258.60%.
ANL's ROE % is ranked worse than 94.82% of 1255
companies
in the Biotechnology industry
Industry Median: -38.18
vs ANL: -424.91
Adlai Nortye (NAS:ANL) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Adlai Nortye ROE % Related Terms
Adlai Nortye ROE % Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adlai Nortye's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's ROE % distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
Adlai Nortye (ANL) has a ROE % of 0.00% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #1190 out of 1255 companies in the Biotechnology industry, placing it in the top 94.8%.
Is Adlai Nortye's ROE % too high?
Adlai Nortye's current ROE % is 0.00%. Based on the distribution chart, Adlai Nortye ranks #1190 out of 1255 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's ROE % compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #1190 out of 1255 companies for ROE %. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current ROE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 